{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:19:26Z","timestamp":1771607966242,"version":"3.50.1"},"reference-count":42,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2022.2161746","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T12:57:14Z","timestamp":1671713834000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-5850","authenticated-orcid":false,"given":"Stephen Maxwell","family":"Montgomery","sequence":"first","affiliation":[{"name":"Costello Medical Consulting Ltd, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Green","sequence":"additional","affiliation":[{"name":"Costello Medical Consulting Ltd, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-6385","authenticated-orcid":false,"given":"Hajer","family":"Karoui","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0414-1225","authenticated-orcid":false,"given":"Richard","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK"},{"name":"Department of Brain Sciences, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1313-4991","authenticated-orcid":false,"given":"Jaclyn","family":"Loh","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Ltd, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.11.015"},{"key":"e_1_3_5_3_1","first-page":"269","volume-title":"Handbook of clinical neurology","author":"Gelfand JM.","year":"2014","unstructured":"Gelfand JM. Chapter 12 - Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. In: Goodin DS, editor. Handbook of clinical neurology. Vol. 122. Elsevier; 2014. p. 269\u2013290."},{"key":"e_1_3_5_4_1","unstructured":"Multiple Sclerosis Trust \u2013 How common is multiple sclerosis? 2022. https:\/\/mstrust.org.uk\/a-z\/how-common-multiple-sclerosis"},{"key":"e_1_3_5_5_1","unstructured":"Multiple Sclerosis Trust. Types of MS. Relapsing remitting MS (RRMS). 2022. https:\/\/www.mssociety.org.uk\/about-ms\/types-of-ms\/relapsing-remitting-ms"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458507084264"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10279-7"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq076"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e3973f"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011163432001"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.04.017"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000096175.39831.21"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq118"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13149"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016"},{"key":"e_1_3_5_18_1","unstructured":"Multiple Sclerosis Trust. Disease modifying therapies. 2022. https:\/\/www.mssociety.org.uk\/about-ms\/treatments-and-therapies\/disease-modifying-therapies."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001139"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0267"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010135"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211010128"},{"key":"e_1_3_5_24_1","unstructured":"National Institute for Health and Care Excellence. Ofatumumab for treating relapsing multiple sclerosis (TA699). 2021. https:\/\/www.nice.org.uk\/guidance\/ta699."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1336099"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614555335"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1345748"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1276070"},{"issue":"2","key":"e_1_3_5_30_1","first-page":"101","article-title":"Long-term survival experience of patients with multiple sclerosis","volume":"29","author":"Pokorski RJ.","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29(2):101\u2013106.","journal-title":"J Insur Med"},{"key":"e_1_3_5_31_1","unstructured":"Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies (NHS England Reference: 170079ALG). 2019. https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2019\/03\/Treatment-Algorithm-for-Multiple-Sclerosis-Disease-Modifying-Therapies-08-03-2019-1.pdf"},{"key":"e_1_3_5_32_1","unstructured":"National Institute for Health and Care Excellence. Siponimod for treating secondary progressive multiple sclerosis (TA656). 2020. https:\/\/www.nice.org.uk\/guidance\/ta656"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01023-8"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0122"},{"key":"e_1_3_5_36_1","unstructured":"National Institute for Health and Care Excellence. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527). 2018. https:\/\/www.nice.org.uk\/guidance\/ta527"},{"key":"e_1_3_5_37_1","unstructured":"National Institute for Health and Care Excellence. Natalizumab for the treatment of adults with highly active relapsing\u2013remitting multiple sclerosis (TA127). 2007. https:\/\/www.nice.org.uk\/guidance\/ta127"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104604"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903433528"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12003"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2020-0034"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1491007"},{"key":"e_1_3_5_43_1","unstructured":"The NHS Long Term Plan. 2019. https:\/\/www.longtermplan.nhs.uk\/wp-content\/uploads\/2019\/08\/nhs-long-term-plan-version-1.2.pdf"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2161746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:19:56Z","timestamp":1701944396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2161746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2161746"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2161746","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}